Published 19 July 2013
MSD, the tradename of US-based Merck, has partnered with Indian pharmaceutical company Lupin to jointly market 23-valent Pneumococcal polysaccharide vaccine (PPV) in the country.
According to the deal, Lupin gains a non-exclusive license to commercialize the vaccine product under a different brand name to address the need of prevention of pneumococcal disease in the region.
The product has a broader coverage and has proven efficacy in preventing pneumococcal diseases caused by bacteria named Streptococcus pneumonia.
MSD India managing director K G Ananthakrishnan said, "This partnership is aligned with our commitment towards patients in India and also addressing treatment challenges for high risk patients by providing broader access to our innovative medicines and vaccines."
Lupin India and CIS group president Shakti Chakraborty said, "This partnership bears testimony to Lupin's leadership credentials in the Indian Pharmaceutical Market (IPM), 2.8 % market share of the overall IPM (IMS TSA MAT, March 2013), not to mention leadership specifically in the Cardiovascular, Diabetes and Respiratory therapy segments as also our existing market reach within the IPM."
Webster Ny Mcdonalds Restaurants Open on Christmas Day santa tracker happy holidays Stores Open On Christmas Day Santa Claus
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.